Logo image of CSCI.CA

COSCIENS BIOPHARMA INC (CSCI.CA) Stock Fundamental Analysis

TSX:CSCI - Toronto Stock Exchange - CA22112H1010 - Common Stock - Currency: CAD

4.98  +0.06 (+1.22%)

Fundamental Rating

3

Overall CSCI gets a fundamental rating of 3 out of 10. We evaluated CSCI against 24 industry peers in the Biotechnology industry. While CSCI seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CSCI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CSCI had negative earnings in the past year.
In the past year CSCI has reported a negative cash flow from operations.
In the past 5 years CSCI always reported negative net income.
CSCI had a negative operating cash flow in each of the past 5 years.
CSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFCSCI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

CSCI's Return On Assets of -56.40% is fine compared to the rest of the industry. CSCI outperforms 62.50% of its industry peers.
With a decent Return On Equity value of -173.14%, CSCI is doing good in the industry, outperforming 70.83% of the companies in the same industry.
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROIC N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
CSCI.CA Yearly ROA, ROE, ROICCSCI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

CSCI has a better Gross Margin (47.26%) than 79.17% of its industry peers.
In the last couple of years the Gross Margin of CSCI has grown nicely.
CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
CSCI.CA Yearly Profit, Operating, Gross MarginsCSCI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSCI has more shares outstanding
Compared to 5 years ago, CSCI has more shares outstanding
The debt/assets ratio for CSCI has been reduced compared to a year ago.
CSCI.CA Yearly Shares OutstandingCSCI.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CSCI.CA Yearly Total Debt VS Total AssetsCSCI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CSCI has an Altman-Z score of -1.21. This is a bad value and indicates that CSCI is not financially healthy and even has some risk of bankruptcy.
CSCI's Altman-Z score of -1.21 is amongst the best of the industry. CSCI outperforms 83.33% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that CSCI is not too dependend on debt financing.
CSCI has a Debt to Equity ratio of 0.19. This is in the better half of the industry: CSCI outperforms 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC8.12%
CSCI.CA Yearly LT Debt VS Equity VS FCFCSCI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.88 indicates that CSCI has no problem at all paying its short term obligations.
The Current ratio of CSCI (2.88) is better than 66.67% of its industry peers.
A Quick Ratio of 2.54 indicates that CSCI has no problem at all paying its short term obligations.
CSCI's Quick ratio of 2.54 is fine compared to the rest of the industry. CSCI outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.54
CSCI.CA Yearly Current Assets VS Current LiabilitesCSCI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.07% over the past year.
The Revenue has grown by 103.93% in the past year. This is a very strong growth!
CSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 80.53% yearly.
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI.CA Yearly Revenue VS EstimatesCSCI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI.CA Yearly EPS VS EstimatesCSCI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI.CA Price Earnings VS Forward Price EarningsCSCI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI.CA Per share dataCSCI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COSCIENS BIOPHARMA INC

TSX:CSCI (6/11/2025, 7:00:00 PM)

4.98

+0.06 (+1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-11 2025-08-11
Inst Owners7.38%
Inst Owner ChangeN/A
Ins Owners1.24%
Ins Owner ChangeN/A
Market Cap15.69M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF N/A
P/B 1.13
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-7.94
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-6.05
FCFYN/A
OCF(TTM)-5.28
OCFYN/A
SpS3.92
BVpS4.41
TBVpS4.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.26%
FCFM N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
F-Score2
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.8%
Cap/Sales 19.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.54
Altman-Z -1.21
F-Score2
WACC8.12%
ROIC/WACCN/A
Cap/Depr(3y)43.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.47%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.32%
OCF growth 3YN/A
OCF growth 5YN/A